Cart
sales@molnova.com
IRAK4-IN-10
CAS No. 2681278-09-9
IRAK4-IN-10( —— )
Catalog No. M35604 CAS No. 2681278-09-9
IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 962 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIRAK4-IN-10
-
NoteResearch use only, not for human use.
-
Brief DescriptionIRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.
-
DescriptionIRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor with an IC50 of 1.5 nM. IRAK4-IN-10 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetIRAK
-
RecptorIRAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2681278-09-9
-
Formula Weight400.48
-
Molecular FormulaC22H24N8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC=1C=CC=2C3=NC=C(C=4N=NN(C4)C5CCNCC5)C(NC(C)C)=C3NC2C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sabnis RW. Novel Tricyclic Heteroaryl Compounds as IRAK4 Inhibitors for Treating Cancer, Autoimmune and Inflammatory Diseases. ACS Med Chem Lett. 2022 Feb 28;13(3):336-337.?
molnova catalog
related products
-
Edecesertib
Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
-
Zabedosertib
Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests.
-
IRAK4-IN-16
A potent, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associate kinase-4 (IRAK4) with IC50 of 2.8 nM.
